No Easy Way Out for Abbott as Deal Target Faces Bribery ProbeBy and
Alere disclosed in March some overseas units are investigated
Corruption cases usually not a deal-breaker, lawyers say
Abbott Laboratories tried to end its $5.8 billion agreement to buy Alere Inc. after finding out in mid-March that the medical-testing company was swept up in a U.S. probe of bribery overseas. Alere’s shares, meanwhile, are trading at levels suggesting that investors have their doubts about the transaction -- at least at the current price.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.